Network pharmacology further pinpointed ten potential targets for the treatment of T2DM combined with CRC, with these genes participating in the insulin signaling pathway, cGMP-PKG signaling pathway, Ras signaling pathway, and Fc-epsilon receptor I signaling pathway. This evidence concerns the gene INS and colorectal carcinoma.